Patient P-01388

Synthetic patientNBL-101 · Day 104 · 25–34 · M · baseline S17Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

92%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S17
Day 82 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 82 CR-01 recommended — Clinician Review CR-01
Day 83 Patient accepted — Started CR-01 in the companion
Day 88 Deterioration detected before clinical escalation — Clinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 82.

Primary contributors, last 14 days

GI instability+25
Treatment adherence-20
Inflammatory activity+19
Nutritional resilience-16
Toxicity+12

What helped?

Clinician Review CR-01Day 82
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

60%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

68.6/100

worsening · +18.0 vs previous 14 d

Toxicity

Blood

53/100

worsening · +13.4 vs previous 14 d

Sleep quality

Wearable

0/100

worsening · -14.2 vs previous 14 d

Energy level

Daily log

2.5/10

worsening · -1.3 vs previous 14 d

Stress level

Daily log

7.5/10

worsening · +1.5 vs previous 14 d

Steps

Wearable

2,923

worsening · -1,307 vs previous 14 d

Adherence

Companion

67.3 %

worsening · -9.8 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 36 from the failing basin, 67 from restoration.

Would help

GI-04 GI Support Protocol
73% improved among 124 similar · onset 8 d · confidence 58%
ME-01 Monitoring Escalation
100% improved among 76 similar · onset 3 d · confidence 69%
NP-02 Dietary Support Protocol
65% improved among 62 similar · onset 10 d · confidence 69%

Would not help

Keep alcohol low
GI +4.1 next day on high-intake days · n 19
Keep histamine low
GI +3.6 next day on high-intake days · n 22
Keep spicy low
GI +2.8 next day on high-intake days · n 12

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Alcohol
+4.1detractor · 95%
Histamine load
+3.6detractor · 95%
Spicy / capsaicin
+2.8detractor · 65%
Dietary fat load
-2.2no signal · 44%
Insoluble fibre
-0.6no signal · 15%
Simple carbohydrates
-0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 69 and rising
- WearableSleep 4.7 h, below personal baseline
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 62
- WearableHRV 27 ms, trending down
Autonomic recovery ↓65
- WearableResting HR 88 bpm
- Wearable2,923 steps/day
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 53

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.1 · butyrate capacity 48/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 5.0 h
Steps: 3,147
Resting HR: 86 bpm

Daily log: GI score 69, nutritional resilience 36, adherence 67.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	23%	S19	AD-05	improved	61
P-01835	51%	S17	CR-01	improved	56
P-01696	45%	S20	CR-01	improved	59
P-01371	42%	S06	CR-01	improved	63
P-01877	41%	S01	CR-01	improved	67
P-01442	38%	S13	CR-01	improved	61
P-01708	36%	S07	CR-01	improved	59
P-01430	23%	S05	CR-01	improved	54
P-01342	23%	S11	DT-01	improved	48
P-01699	41%	S04	GI-04	improved	69
P-01393	33%	S14	GI-04	improved	53
P-01725	33%	S18	GI-04	no change	56